Vizgen Valuation, Funding & Investors

Vizgen is valued at $31M as of January 2020.

Last Vizgen valuation

$31M

Series A · Jan 2020

Last Vizgen funding round

$48M

Series E · Jan 2026

Cumulative funding Vizgen raised

$184M

across 4 funding rounds

Key investors in Vizgen

  • ARCH Venture Partners
  • Northpond Ventures
  • Tao Capital Partners
  • Novalis LifeSciences
  • M Ventures
  • Sofina

Vizgen Overview

About Vizgen

Vizgen is a Boston-headquartered biotech firm advancing MERFISH spatial transcriptomics technology for single-cell RNA imaging. The platform achieves genome-scale analysis with subcellular resolution, enabling researchers to map gene expression in tissues. Vizgen's MERSCOPE systems serve academic labs and pharma companies like Merck, supporting drug discovery in oncology and neuroscience since 2020.


Founded

2019

HQ

United StatesUnited States

Website

vizgen.com

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$31M (Jan 2020)

Vizgen Valuation

Vizgen is currently valued at $31M, based on its Series A in January 2020.

The $14M round was led by ARCH Venture Partners and Northpond Ventures.

Vizgen valuation by funding round

Vizgen valuation by funding round
DateStageValuation
Jan 2020Series A$31M

Vizgen Funding History

Vizgen has raised a total of $184M across 4 funding rounds.

Vizgen's first fundraising round was a $14M Series A in January 2020. The most recent completed round was a $48M Series E in January 2026.

Vizgen funding rounds

Vizgen funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jan 2026Series EARCH Venture Partners (lead); M Ventures (lead); Northpond Ventures (lead)$48M-Vizgen, a leader in spatial multi-omics, closed a $48 million financing round on January 8, 2026, led by ARCH Venture Partners, co-led by M Ventures and Northpond Ventures, with participation from existing investors. The company pioneered single-cell spatial genomics with its 2022 MERSCOPE platform launch and continues innovating with products like MERSCOPE Ultra and MERFISH 2.0. Proceeds will fund execution of the innovation roadmap, global researcher service expansion, manufacturing scale-up, commercial capabilities enhancement, custom product turnaround acceleration, operations optimization for margin improvement, and customer education at a global scale. CEO Rob Carson, who joined in 2024 post-merger with Ultivue, stated the financing positions Vizgen to march toward profitability after resolving prior litigation and raising funds since late 2025. The round supports a path to profitability without a specified timeline, emphasizing customer experience excellence and making spatial multi-omics accessible to every research lab. Vizgen bolstered protein and co-detection capabilities in 2025, introduced class-leading chemistry, and debuted a revamped website in early 2026. In the competitive spatial biology field, Vizgen differentiates through technical excellence amid past legal disputes with peers like 10X Genomics and Harvard, now settled. The company plans to debut its spatial multi-omics roadmap at AGBT 2026 and presented data at prior events like SITC 2025. With 134 employees as of recent estimates, Vizgen aims to scale production and sales of instruments and reagents mapping gene and protein expression across cells.
Jun 2022Series CARCH Venture Partners (lead); Blue Water Life Science Advisors (lead); Tao Capital Partners; Northpond Ventures; Novalis LifeSciences; Sofina$85M-Vizgen is a spatial genomics company pioneering single-cell spatial transcriptomics (SST) technology. The company provides tools and platforms including MERFISH technology and MERSCOPE for in situ single-cell spatial genomics, along with InSituPlex assays and STARVUE spatial image analysis technology. These tools enable researchers to uncover insights into human biology and mechanisms of complex diseases. Vizgen raised $85.2M in its Series C round that closed on May 5, 2022, led by ARCH Venture Partners along with Blue Water Life Science Advisors, David Walt, Northpond Ventures, Novalis LifeSciences, Sofina, Tao Capital Partners, and undisclosed investors. The company has raised a total of $187.7M across multiple funding rounds as of January 2026. Vizgen later acquired Ultivue, combining MERFISH technology with InSituPlex assays and STARVUE analysis technology. The company was named the #1 private spatial biology company of 2024 by Genetic Engineering & Biotechnology News and is headquartered in Cambridge, Massachusetts.
Apr 2021Series BNorthpond Ventures (lead); Novalis LifeSciences (lead); Tao Capital Partners; David R. Walt; Pura Vida Investments; ARCH Venture Partners$37M-Vizgen, a life science company focused on advancing human health through single-cell spatial genomics, closed a $37 million oversubscribed Series B financing on April 7, 2021, co-led by Novalis LifeSciences and Northpond Ventures. Participating investors included new backers Tao Capital Partners, Pura Vida Investments, and a large U.S. endowment fund, alongside existing investors ARCH Venture Partners and David R. Walt, a Harvard Medical School professor, Wyss Institute core faculty, and Vizgen co-founder. The funding aimed to accelerate company growth, expand infrastructure, and support the full commercial launch of the MERSCOPE platform, which enables sub-cellular spatial resolution gene expression profiling, in summer 2021. Vizgen's MERSCOPE technology leverages proprietary MERFISH (multiplexed error-robust fluorescence in situ hybridization) for spatially resolved single-cell transcriptomics, providing unprecedented insights into molecular and cellular organization in healthy and pathological tissues. This builds on the company's earlier $14 million Series A in January 2020, led by ARCH Venture Partners and Northpond Ventures, which initiated productization of the platform for research, drug discovery, clinical pathology, and diagnostics. Leaders like Northpond's Andrea Jackson highlighted Vizgen's role in enabling novel spatial genomics research, while CEO Terry Lo emphasized the profound impact of spatial data acceleration in genomics. No financial metrics such as post-money valuation, revenue, ARR, EBITDA, or valuation multiples were disclosed for this round. Vizgen continued operations post-Series B, with later developments including a 2026 $48 million financing led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures to scale manufacturing, innovate (e.g., MERSCOPE Ultra, MERFISH 2.0), and pursue profitability after resolving prior litigation.
Jan 2020Series AARCH Venture Partners (lead); Northpond Ventures (lead)$14M$31MVizgen launched on January 30, 2020, with a $14 million Series A financing co-led by ARCH Venture Partners and Northpond Ventures to accelerate productization of its patented MERFISH platform for spatially resolved, single-cell transcriptomics. The post-money valuation stood at $31.11 million. The platform aims to provide unprecedented insights into molecular and cellular organization in healthy and pathological tissues, advancing data-driven drug discovery, clinical pathology, and diagnostics. ARCH Venture Partners, a major early-stage venture firm focused on life sciences innovations, and Northpond Ventures, a global VC dedicated to science and technology, co-led the round. Northpond's Sharon Kedar joined the Vizgen board. The financing supported the company's initial development from its Cambridge, Massachusetts base, leveraging technology validated for research and potential clinical applications.

Who has invested in Vizgen?

9 investors have backed Vizgen across its funding rounds, including ARCH Venture Partners, Northpond Ventures, Tao Capital Partners, Novalis LifeSciences, M Ventures and Sofina.

Lead investors include ARCH Venture Partners, M Ventures, Northpond Ventures, Blue Water Life Science Advisors and Novalis LifeSciences.


Vizgen Investors

Investors in Vizgen by funding rounds participated
InvestorHQRoundsRoleFirst check
Northpond VenturesUnited StatesWashington, DC4LeadJan 2020
ARCH Venture PartnersUnited StatesChicago, IL4LeadJan 2020
Tao Capital PartnersUnited StatesSan Francisco, CA2ParticipantApr 2021
Novalis LifeSciencesUnited StatesNorfolk, VA2LeadApr 2021
M VenturesNetherlandsAmsterdam1LeadJan 2026
David R. WaltUnited StatesBoston, MA1ParticipantApr 2021
Pura Vida InvestmentsUnited StatesNew York City, NY1ParticipantApr 2021

This data is available for Pro users. Sign up to see all 9 Vizgen investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Vizgen

Vizgen has acquired 1 company to date.

Last acquisition by Vizgen was on October 9th 2024. Vizgen acquired Ultivue for undisclosed valuation.


Latest Acquisitions by Vizgen

Ultivue
Description
Ultivue is a Cambridge-based life sciences company specializing in spatial biology reagents for tissue multiplexing. Its Ultiplex and PanCK panels enable simultaneous detection of up to eight biomarkers in immunofluorescence assays on platforms like Akoya and Leica. Acquired by Danaher in 2021, Ultivue supports pathology research in oncology and immunology at leading academic centers worldwide.
HQ CountryUnited States
HQ City
-
Deal Date9 Oct 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Vizgen acquisitions and their M&A valuation multiples.

Start Free Trial

Vizgen Competitors

Vizgen competitors include listed companies like Korro Bio and Microba Life Sciences, and private ones like 20/20 Gene Systems, Prevencio, Transition Bio and Dynamic Code.

Public and private companies comparable to Vizgen
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
20/20 Gene SystemsUnited StatesUnited StatesPrivate--$32M-
Korro BioUnited StatesUnited StatesPublicly listed$6M($112M)$174M48.9x
PrevencioUnited StatesSeattle, WAPrivate--$33M-
Microba Life SciencesAustraliaAustraliaPublicly listed$11M($8M)$27M2.1x
Transition BioUnited StatesUnited StatesPrivate--$27M-
Dynamic CodeSwedenLinköpingPrivate--$27M-

Vizgen Public Comps

Vizgen is still privately-owned, but its public comps include Pathkey.AI, Cleo Diagnostics, LSL Pharma Group, Sona Nanotech, Optimi Health, Genoway, Bio-Works Technologies, Microba Life Sciences, IMBdx and Abingdon Health.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Pathkey.AI$20K($972K)1385.3x-(28.2x)-
Cleo Diagnostics------
LSL Pharma Group$21M$2M3.1x-39.4x-
Sona Nanotech-($2M)--(16.2x)-
Optimi Health$305K($2M)74.5x-(14.1x)-
Genoway$24M$6M1.7x1.6x7.3x9.8x
Bio-Works Technologies$6M($2M)4.8x-(17.5x)-
Microba Life Sciences$11M($8M)2.2x2.1x(3.1x)(3.2x)

This data is available for Pro users. Sign up to see all Vizgen competitors and their valuation data.

Start Free Trial

Common questions about Vizgen

When was Vizgen founded?Vizgen was founded in 2019.
Where is Vizgen headquartered?Vizgen is headquartered in United States.
Is Vizgen publicly listed?No, Vizgen is a private, VC-backed company.
What is Vizgen's valuation?Vizgen was last valued at $31M in its Series A in January 2020.
How much funding has Vizgen raised?Vizgen has raised $184M across 4 funding rounds.
What was Vizgen's last funding round?Vizgen's last funding round was a $48M Series E in January 2026, led by ARCH Venture Partners, M Ventures and Northpond Ventures.
Who are Vizgen's investors?Vizgen's investors include Northpond Ventures, ARCH Venture Partners, Tao Capital Partners, Novalis LifeSciences, M Ventures, David R. Walt, Pura Vida Investments, Sofina and Blue Water Life Science Advisors.
Which companies are comparable to Vizgen?Companies comparable to Vizgen include 20/20 Gene Systems, Korro Bio, Prevencio, Microba Life Sciences, Transition Bio and Dynamic Code.
How many companies has Vizgen acquired?Vizgen has acquired 1 company, including Ultivue.

See companies similar to Vizgen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial